Biography
Charles Ching is a partner in the Corporate Department and heads the Firm’s Asia practice. He represents financial sponsors and corporate clients on cross-border M&A and investment transactions, with particular focus on private equity investments in Asia, outbound M&A by Asian investors, and regional joint ventures and other corporate transactions. He regularly advises clients on some of the most complex and noteworthy public and private M&A transactions in the United States and globally, having practiced in New York and Hong Kong.
Charles is recognized as a leading transactional lawyer by Chambers Asia-Pacific and Legal 500 Asia Pacific, and is cited as a “Highly Regarded” lawyer for M&A by IFLR1000 Asia-Pacific. “[S]tands out of the crowd” with “unmatched knowledge in both Chinese and international private equity and M&A market”, clients are impressed by his “ability to influence and negotiate across the table” and his “partnership approach to working with clients”, according to Chambers and Legal 500.
Charles was named among “The Visionaries” in China Business Law Journal’s annual “A-List” for 2023-2024, and was included in the same list for 2018 and 2019 as one of the leading 100 lawyers in foreign firms in China. He was also recognized in Asia Legal Business’ 2023 China Dealmakers list and its 2022 Asia Dealmakers list, as well as in The Best Lawyers™ in China for 2020, with the particular distinction of being the 2020 Private Equity and Venture Capital “Lawyer of the Year” in Shanghai.
Charles' recent representations include:
- Advent International in multiple matters, including (1) the investment in VNU Exhibitions Asia (now Globus Events), a leading host of exhibitions and conferences in China, (2) the investment in LBS Group, a leading pest control operation and hygiene solutions provider, (3) the acquisition of a majority stake in Wagas Group, a leading lifestyle F&B group, (4) the acquisition of a majority stake in GS Capsule, the largest domestic capsule provider in China, and (5) the acquisition by BioDuro, LLC (a portfolio company of Advent International), a global life sciences contract research and development organization, of Sundia MediTech Company Ltd., a provider of life sciences research, development and manufacturing services based in China
- Tianjin Zhonghuan Semiconductor Co. Ltd. (now known as TCL Zhonghuan Renewable Energy) as sponsor investor in the approximately $1 billion sponsored spin-off and listing of Maxeon Solar Technologies, Ltd., the non-US solar panel and solar cell manufacturing operations previously owned by SunPower Corporation, and certain follow-on investments
- FountainVest Partners in multiple matters, including (1) as lead investor in the $750 million Series E funding round for Zuoyebang Education Limited, a leading developer and operator of online after-school tutoring programs for K-12 students in China and (2) as lead investor in the Series D funding round for Broncus Medical, Inc., a developer and commercializer of medical devices for the diagnosis and treatment of lung cancer
- Primavera Capital in multiple matters, including (1) as lead investor in the funding round for Xingsheng Youxuan, a chain of small neighborhood convenience stores in China that operates an e-commerce platform for the sale of fresh produce, (2) the investment in Local Services Holding, one of China’s leading digital services platforms, (3) the investment in Kuaishou Technology, a provider of internet media services and (4) the investment in Koubei, an on-demand local services platform in China, as part of Koubei’s $1.1 billion equity financing round
- Warburg Pincus in multiple matters, including (1) the investment in Jinxin Fertility, one of China’s leading assisted reproductive services providers, (2) a joint venture with a leading life sciences company and (3) various China healthcare investments including Hygeia and Evercare
- Montagu Private Equity in the acquisition of ISI Emerging Markets Group Ltd., a digital provider of hard-to-obtain macroeconomic, company and industry intelligence on global emerging markets, from CITIC Capital and Caixin Global
- Sun Capital Partners in the acquisition by Vetrerie Riunite Group (a portfolio company of Sun Capital Partners), a global leading manufacturer of technical glass for household appliances, of Suizhong Minghui Industrial Technology Co, Ltd., one of the largest Chinese household appliance glass manufacturers
- Boquan He, as Vice Chairman and member of a consortium, in the $1.1 billion take-private of iKang Healthcare Group, one of the largest providers of preventative healthcare services in China
- SoftBank Vision Fund in the $2 billion investment in Coupang, one of South Korea’s largest online retailers
- Shanghai Pharmaceuticals in the $1.2 billion acquisition of U.S.-based Cardinal Health’s pharmaceutical and medical products distribution business in China
- HNA Group in multiple matters, including (1) the $6.5 billion acquisition of a 25% stake in Hilton Inc., Park Hotels & Resorts Inc. and Hilton Grand Vacations Inc. (collectively, formerly known as Hilton Worldwide Holdings) from Blackstone and (2) in connection with the $6 billion acquisition of U.S.-listed Ingram Micro, an IT logistics and solutions provider, by Tianjin Tianhai Investment Company
- A sovereign wealth fund in an investment in TutorGroup Co Ltd., an online provider of education services in China
- Oaktree Capital in the sale of the Axilone business to CITIC Capital
- Hillhouse Capital in multiple matters, including as an investor in Mogujie.com, a large fashion-focused e-commerce service in China, and in Meilishuo.com, an online women’s apparel retailer, in the $3 billion merger of equals of Mogujie.com and Meilishuo.com
- A technology fund investing in Bytedance, a leading Chinese internet conglomerate
- Avolon Holdings, an aircraft leasing and management services provider, in the $7.6 billion acquisition of the company by Bohai Leasing
Charles is qualified in New York and Hong Kong. He is a native Mandarin speaker.